ETNB - 89bio's Fatty Liver Candidate Shows Long-Term Improvement: Details | Benzinga
89bio Inc (NASDAQ: ETNB) released topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis (NASH).
At week 48, the 30mg weekly (QW) and 44mg every two weeks (Q2W) dosing schedules of pegozafermin demonstrated statistically significant improvements across key markers of liver health.
The benefits observed at week 48 were consistent with the results observed at week 24, indicating sustained benefits over time.
Consistent with ...